Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Clinical Oncology: Case Reports
Sara Galimberti Author
Subjects of specialization
Affiliation
Lymphoma, Multiple Myeloma, Hematologic Diseases, CLL, Myelodysplastic Syndromes, cancer oncology
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Biography
Sara Galimberti currently works at the Department of Clinical and Experimental Medicine, Università di Pisa. Sara does research in Oncology and Hematology. Their current project is resistance to TKIs in CML, pharmacogenomics, minimal residual disease in lymphoma and myeloma
Publications
Case Report Open Access
The Combination of Ponatinib and Alpha-Interferon can Improve Outcome of Resistant Chronic Myeloid Leukemia Patients
Author(s): Claudia Barate*, Simona Soverini, Elisabetta Abruzzese, Francesca Guerrini, Susanna Grassi, Maria Immacolata Ferreri, Federica Ricci, Serena Balducci, Mario Petrini and Sara Galimberti
Abstract
The most of patients affected by chronic myeloid leukemia is cured with Tyrosine Kinase Inhibitors (TKI). However, about 30% must change therapies for intolerance or poor efficacy. The failure of therapy is associated in the majority of cases to the appearance of ABL1 mutations. Ponatinib (ICLUSIG, INCYTE®) is able to overcome most of the known mutations, including the T315I. But when compound mutations appear, the TKIs alone are not enough and a combination therapy is required to overcome this condition.
We describe here the evolution of the mutational status of 3 patients with compound mutations, treated with the association of ponatinib plus alfa interferon. This combination resulted safe and effective for all.
In... view more»
Google Scholars / Researchers Sites
